A Study of SI-F019 in Healthy Participants

Phase 1 Completed 36 enrolled Sichuan Baili Pharmaceutical Co., Ltd. SystImmune Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability and pharmacokinetic properties of a single intravenous administration of SI-F019 recombinant human bivalent ACE2-Fc fusion protein injection in healthy participants, and provide a basis for the design of subsequent clinical trials.

Timeline

Start: 2021-03-30
Primary completion: 2021-09-20
Completion: 2021-09-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SI-F019	Protein / enzyme biologic	—	Intravenous

Indications

No indication recorded.